Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

Benchmarks Nifty22,788.0034.8FEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.32 % Invest NowFEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.45 % Invest NowEnter search text:

The Economic Times daily newspaper is available online now. Read Today's Paper Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 croreBy Surbhi Khanna, ET OnlineLast Updated: Oct 27, 2026, 12:55:00 PM ISTSynopsis

Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points.

Mankind Pharma shares jumped nearly 8% on Tuesday to an intraday high of Rs 2,500 on the NSE after the company reported a 38% year-on-year rise in Q2 profit after tax (PAT) to Rs 716 crore, while revenue grew 17% over the same period.

According to an exchange filing, the company posted a 37.7% rise in profit to Rs 716 crore in the September quarter, from Rs 520.2 crore in the year-ago period, driven by strong business growth in domestic and international markets.

Also Read | Mankind Pharma Q2 profit rises 38% to Rs 716 crore

Revenue from operations rose to Rs 4,337.9 crore during the quarter under review, compared with Rs 3,697.2 crore in the year-ago period, registering a 17.3% growth. Domestic revenue stood at Rs 3,657 crore, registering a jump of 14.8%, while exports stood at Rs 681 crore, up 32.7% year-on-year.

EBITDA was recorded at Rs 1,175 crore, up from Rs 924 crore in Q2FY26. The EBITDA margin stood at 27.1%, up 210 bps year-on-year, while the PAT margin stood at 16.5%, up 240 bps YoY.

Live Events

“Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth,” said Rajeev Juneja, Vice Chairman & Managing Director.

Domestic business

The domestic pharmaceutical business, excluding consumer healthcare, grew 15.9%, driven by strong performance in both chronic and acute therapies. Cardiac therapies recorded growth of around 19%, while anti-diabetes products grew 16%. Meanwhile, the company’s international business expanded 33%, while OTC witnessed muted growth in Q2.

The company also highlighted that it has consistently maintained its number one rank over the last nine years, with a prescription share of 15.2% and prescriber penetration of 84.4% in MAT Aug’26. Secondary sales grew 15.7%, exceeding the Indian Pharmaceutical Market’s (IPM) growth of 14.2% and representing 1.1 times the market’s growth rate.

Consumer healthcare business

Revenue growth was impacted by slower offtake in the industry category and some regional impact in the East and South. Despite softer growth, the company gained market share in key brands, Manforce and Preganews. The MT & E-Com share increased to 18% in Q2FY27, compared with 12% in Q2FY26, supported by 55% growth.

Exports

International revenue increased by 33% in Q2FY27, driven by strong growth in both Mankind and BSV International. The company launched 1 new product in Q2FY27, taking the total number of products launched in the US to 50.

In its exchange filing, the company said that revenue from operations in the first half of FY27 stood at Rs 8,368 crore, up 15.1% YoY. Domestic revenue stood at Rs 7,082 crore, up 12.7%, while exports stood at Rs 1,286 crore, up 31.0% YoY.

Also Read | Mankind Pharma shares key business developments from Q2 & H1 of FY27

During the same period, the EBITDA margin stood at 26.7%, up 230 bps YoY, while the PAT margin stood at 15.4%, up 210 bps YoY. Diluted EPS stood at Rs 30.9, up 34.6% YoY (FV Re 1).

Mankind Pharma share price movement

Over the last one week, the stock gained 10.58% and was marginally up by 0.68% over the last one month. So far in 2026, the stock has gained 15.11%. Shares of Mankind Pharma were up 3.10% over the last one year and nearly 41.67% over the last three years.

Disclosure: This article has been written by Surbhi Khanna, who is not a SEBI-registered Research Analyst or an investment advisor. Surbhi Khanna does not hold any financial interest in Economic Times as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of the EconomicTimes Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onmankind pharmaMankind Pharma share priceMankind Pharma Q2 resultsMankind Pharma profitMankind Pharma revenuepharma stocksMankind Pharma EBITDApharmaceutical sectorMankind Pharma exports

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

...moreless
(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onmankind pharmaMankind Pharma share priceMankind Pharma Q2 resultsMankind Pharma profitMankind Pharma revenuepharma stocksMankind Pharma EBITDApharmaceutical sectorMankind Pharma exports

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

...morelessPrime ExclusivesInvestment IdeasStock Report PlusePaperWealth Edition

• KYC and KYB: Inside Damani’s Avenue Supermarts that refuses to charge more – Part 1 of 3

• Will oil turn into a lingering problem? Is the world economy, India, or the market prepared?

• KYB and KYC: Business behind the wealth creator called ‘Divi’s Lab’ – Part 2, concluding

• KYB and KYC: Business behind the wealth creator called “Divi’s Lab” – Part 1

• The global business of promising more

• One company, 2 words. Bond yield and CDS: Will they decide the fate of global markets?

• 1
• 2
• 3

View all StoriesContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Login using your ET Prime credentials to enjoy all member benefits

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Big Price Drop! Flat 40% Off

Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail OfferAvail OfferClaim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '

' + h3 + '

' + h4 + '

' + listing + '

'; $('#paidSCWidget').html(html); var callback = $('#paidSCWidget').attr('data-callback'); if(callback && window[callback]) { window[callback](); } customDimension.dimension72 += ' | Shown SYFT no Trial_With Missed Paywalled Articles Collection'; } else { _processNormal() } } }); } else { _processNormal(); } } catch (e) { _processNormal(); } }, function () { _processNormal(); }); //console.log('storyCollectionLoad', $); }

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with
in-depth insights that matter

• Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

  What Adani’s US indictment means for India Inc’s overseas fundraising

• Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

  Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?

• Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

  The problem with lab grown diamonds

• Why a falling rupee is a better option for the economy

  A list of top 20 momentum stocks that have delivered massive returns in one year

2Invest Wisely With Smart Market Tools & Investment Ideas

Alpha Trade

Get daily trade ideas from SEBI-registered research analysts.

Investment Ideas

Grow your wealth with stock ideas & sectoral trends.

Stock Reports Plus

All-in-one stock research with Stock Score, peer comparison & key signals.

BigBull Portfolio

Get to know where the market bulls are investing to identify the right stocks.

Stock Analyzer

Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.

Market Mood

Analyze the market sentiments & identify the trend reversal for strategic decisions.

Stock Talk Live at 9 AM Daily

Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.

3Stay informed anytime, anywhere with ET ePaper

ePaper - Print View

Read the PDF version of ET newspaper. Download & access it offline anytime.

ePaper - Digital View

Read your daily newspaper in Digital View & get it delivered to your inbox everyday.

Wealth Edition

Manage your money efficiently with this weekly money management guide.

TOI ePaper

Read the PDF version of TOI newspaper. Download & access it offline anytime.

Deep Explainers

Explore the In-depth explanation of complex topics for everyday life decisions.

Health+ Stories

Get fitter with daily health insights committed to your well-being.

Personal Finance+ Stories

Manage your wealth better with in-depth insights & updates on finance.

5Enjoy Complimentary Subscriptions From Top Brands

Stream new documentaries from all across the world every day.

Stories you might be interested in